Lv1
20 积分 2023-11-28 加入
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
1天前
已完结
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
13天前
已完结
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
13天前
已完结
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
14天前
已完结
HER2 and Breast Cancer — A Phenomenal Success Story
27天前
已完结
Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance
27天前
已完结
Abstract P3-10-13: A Comprehensive Analysis of Dysregulation in the PTEN/PI3K/AKT Pathway in Breast Cancer Among the Chinese Population
1个月前
已关闭
Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study
1个月前
已完结
Estrogen and progesterone signalling in the normal breast and its implications for cancer development
1个月前
已完结
Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052
1个月前
已完结
皖公网安备34019202002308
